On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

Eli Lilly announced data demonstrating more patients with moderately to severely active Crohn’s disease treated with ...

Shares of drug maker Eli Lilly ($LLY) were little changed at the time of writing despite announcing results from its Phase 3 ...

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...

Eli Lilly LLY announced encouraging data from the phase III VIVID-1 study, which evaluated its IL-23p19 antibody mirikizumab for adult patients with moderate-to-severe Crohn’s disease (“CD”).

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would ...

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, but a win in a head-to-head trial against Novartis’ big-selling Cosentyx could ...